GT201700163A - Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) - Google Patents

Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)

Info

Publication number
GT201700163A
GT201700163A GT201700163A GT201700163A GT201700163A GT 201700163 A GT201700163 A GT 201700163A GT 201700163 A GT201700163 A GT 201700163A GT 201700163 A GT201700163 A GT 201700163A GT 201700163 A GT201700163 A GT 201700163A
Authority
GT
Guatemala
Prior art keywords
miocardiopathy
mcd
dilated
treatment
urea
Prior art date
Application number
GT201700163A
Other languages
English (en)
Inventor
Oslob Johan
Aubele Danielle
Kim Jae
Mcdowell Robert
Song Yonghong
Sran Arvinder
Zhong Min
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of GT201700163A publication Critical patent/GT201700163A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA NUEVOS COMPUESTOS DE PIPERIDINA UREA 4-METILSULFONA-SUSTITUIDOS QUE SON ÚTILES PARA EL TRATAMIENTO DE MIOCARDIOPATÍA DILATADA (MCD) Y AFECCIONES ASOCIADAS A DISFUNCIÓN SISTÓLICA O RESERVA SISTÓLICA VENTRICULAR IZQUIERDA Y/O DERECHA. SE DESCRIBEN LA SÍNTESIS Y LA CARACTERIZACIÓN DE LOS COMPUESTOS, ASÍ COMO MÉTODOS PARA TRATAR MCD Y OTRAS FORMAS DE ENFERMEDAD CARDÍACA.
GT201700163A 2015-01-22 2017-07-20 Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) GT201700163A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
GT201700163A true GT201700163A (es) 2018-10-18

Family

ID=55275230

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700163A GT201700163A (es) 2015-01-22 2017-07-20 Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)

Country Status (35)

Country Link
US (1) US9925177B2 (es)
EP (2) EP3247707B1 (es)
JP (1) JP6712275B2 (es)
KR (2) KR20230145504A (es)
CN (3) CN107428719B (es)
AU (3) AU2016209200B2 (es)
BR (1) BR112017015627B1 (es)
CA (1) CA2974370C (es)
CL (1) CL2017001871A1 (es)
CO (1) CO2017008398A2 (es)
CR (1) CR20170370A (es)
DK (1) DK3247707T3 (es)
DO (2) DOP2017000166A (es)
EA (1) EA036923B1 (es)
EC (1) ECSP17054181A (es)
ES (1) ES2953480T3 (es)
FI (1) FI3247707T3 (es)
GT (1) GT201700163A (es)
HK (1) HK1246775A1 (es)
HR (1) HRP20230737T1 (es)
HU (1) HUE063410T2 (es)
IL (5) IL295547A (es)
LT (1) LT3247707T (es)
MX (3) MX2021010778A (es)
PE (2) PE20212253A1 (es)
PH (1) PH12017501279A1 (es)
PL (1) PL3247707T3 (es)
PT (1) PT3247707T (es)
RS (1) RS64432B1 (es)
SG (2) SG10201913047UA (es)
SI (1) SI3247707T1 (es)
TN (1) TN2017000320A1 (es)
UA (1) UA119905C2 (es)
WO (1) WO2016118774A1 (es)
ZA (1) ZA201704777B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CN111601798B (zh) 2017-09-13 2023-08-11 美国安进公司 双酰胺肌节活化化合物及其用途
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
CA3090204A1 (en) * 2018-02-01 2019-08-08 MyoKardia, Inc. Pyrazole compounds and preparation thereof
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
US20220265629A1 (en) * 2019-05-19 2022-08-25 MyoKardia, Inc. Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
AU2020315605A1 (en) * 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
EP4164644A1 (en) * 2020-06-15 2023-04-19 MyoKardia, Inc. Treatment of atrial dysfunction
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CN116082326A (zh) * 2022-12-16 2023-05-09 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
AU2005264988B2 (en) * 2004-06-17 2011-09-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CN102596949B (zh) * 2009-11-11 2015-08-19 大日本住友制药株式会社 8-氮杂双环[3.2.1]辛烷-8-甲酰胺衍生物

Also Published As

Publication number Publication date
AU2023200361A1 (en) 2023-02-23
MX2022007040A (es) 2022-06-24
PL3247707T3 (pl) 2023-12-11
EA036923B1 (ru) 2021-01-15
EA201791656A1 (ru) 2017-11-30
IL271034A (en) 2020-01-30
WO2016118774A1 (en) 2016-07-28
CL2017001871A1 (es) 2018-04-13
JP6712275B2 (ja) 2020-06-17
ZA201704777B (en) 2023-07-26
ECSP17054181A (es) 2019-02-28
US20160243100A1 (en) 2016-08-25
DOP2017000166A (es) 2017-10-15
BR112017015627B1 (pt) 2022-11-16
RS64432B1 (sr) 2023-09-29
AU2020244490A1 (en) 2020-10-29
CA2974370A1 (en) 2016-07-28
EP3247707A1 (en) 2017-11-29
AU2016209200A1 (en) 2017-08-10
CN107428719B (zh) 2020-03-27
LT3247707T (lt) 2023-08-25
SI3247707T1 (sl) 2023-10-30
SG10201913047UA (en) 2020-02-27
CA2974370C (en) 2023-10-31
EP4234017A2 (en) 2023-08-30
KR20170113578A (ko) 2017-10-12
IL286369A (en) 2021-10-31
IL253552B (en) 2019-12-31
EP4234017A3 (en) 2023-10-18
UA119905C2 (uk) 2019-08-27
PT3247707T (pt) 2023-08-31
CR20170370A (es) 2017-10-20
KR20230145504A (ko) 2023-10-17
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31
HUE063410T2 (hu) 2024-01-28
JP2018502883A (ja) 2018-02-01
IL295547A (en) 2022-10-01
DK3247707T3 (da) 2023-07-03
KR102585550B1 (ko) 2023-10-10
PH12017501279A1 (en) 2018-01-29
IL253552A0 (en) 2017-09-28
MX2021010778A (es) 2022-08-11
FI3247707T3 (fi) 2023-08-22
HK1246775A1 (zh) 2018-09-14
SG11201705928XA (en) 2017-08-30
HRP20230737T1 (hr) 2023-10-13
PE20171511A1 (es) 2017-10-20
MX2017009540A (es) 2017-10-20
PE20212253A1 (es) 2021-11-24
CN118164961A (zh) 2024-06-11
DOP2022000172A (es) 2022-09-30
TN2017000320A1 (en) 2019-01-16
BR112017015627A2 (pt) 2018-03-13
CN111393414A (zh) 2020-07-10
IL279247A (en) 2021-01-31
AU2020244490B2 (en) 2022-12-01
AU2016209200B2 (en) 2020-07-02
US9925177B2 (en) 2018-03-27
CN107428719A (zh) 2017-12-01
CN111393414B (zh) 2024-05-07
ES2953480T3 (es) 2023-11-13
NZ734020A (en) 2023-11-24

Similar Documents

Publication Publication Date Title
GT201700163A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
CR20160032A (es) Compuestos de pirimidinodiona contra estados cardíacos
CO2017002191A2 (es) Inhibidores de desmetilasa-1 específica a lisina
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
ECSP17006821A (es) Inhibidores de la desmetilasa-1 específica de la lisina
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
ECSP17006776A (es) Inhibidores de la desmetilasa-1 específica de la lisina
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
UY35745A (es) Derivados sustituidos de fenilalanina
CR20150148A (es) Azaindolinas
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
CL2017002304A1 (es) Métodos para tratar enfermedades
EA201791388A1 (ru) Общий синтез триоксакарцина dc-45-a2 и получение аналогов триоксакарцина
CY1124597T1 (el) Εκχυλισμα λαδιου gynura procumbens για τη θεραπεια διαφορων δερματολογικων ασθενειων και η διαδικασια παρασκευης του
NZ772098A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)